GlassScriptPhysician profile
William J Lavery
NPI 1457779605
$24,695.91
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $164 · 2021: $1,365 · 2022: $2,504 · 2023: $12K · 2024: $8,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $4,784 · Food and Beverage: $1,973 · Travel and Lodging: $174 · Education: $94.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,325.00 |
| Consulting Fee | $4,784.45 |
| Food and Beverage | $1,973.24 |
| Travel and Lodging | $174.20 |
| Education | $94.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $9,520.50 | 2021-2024 | Xolair |
| Glaxosmithkline, LLC. | $5,963.55 | 2020-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $5,369.21 | 2020-2024 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $1,807.93 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $860.76 | 2019-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $244.27 | 2021-2024 | Hyqvia, Takhzyro |
| Biocryst US Sales Co., LLC | $146.13 | 2021-2024 | Orladeyo |
| Pfizer INC. | $113.20 | 2019-2023 | |
| Amgen INC. | $92.97 | 2022-2024 | Tezspire |
| Grifols USA, LLC | $60.26 | 2023-2024 | Xembify |
| Hospira, INC. | $56.49 | 2022-2024 | |
| Abbvie INC. | $52.08 | 2022-2024 | |
| Csl Behring | $48.92 | 2022-2023 | Kcentra, Haegarda |
| Pharming Healthcare, INC. | $47.05 | 2021-2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $46.23 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $42.35 | 2022-2023 | Adbry |
| Novartis Pharmaceuticals Corporation | $36.01 | 2023 | |
| Kaleo, INC. | $35.03 | 2022-2023 | Auvi-Q |
| Grifols Shared Services North America, INC. | $30.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2021 | |
| Optinose US, INC. | $22.53 | 2022 | |
| Blueprint Medicines Corporation | $21.65 | 2023 | Ayvakit |
| Regeneron Pharmaceuticals, INC. | $19.80 | 2023 | Dupixent |
| Adma Biomanufacturing LLC | $18.20 | 2023 | |
| Merck Sharp & Dohme LLC | $16.17 | 2023 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lavery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.